The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
anticorps MKI67, anticorps kia, anticorps mki67, anticorps MGC132156, anticorps D630048A14Rik, anticorps Ki-67, anticorps Ki67, anticorps KIA, anticorps MIB-1, anticorps marker of proliferation Ki-67, anticorps marker of proliferation Ki-67 L homeolog, anticorps marker of proliferation Ki-67 S homeolog, anticorps antigen identified by monoclonal antibody Ki 67, anticorps antigen identified by monoclonal antibody Ki-67, anticorps nucleolar protein interacting with the FHA domain of MKI67, anticorps MKI67, anticorps mki67, anticorps mki67.L, anticorps mki67.S, anticorps Mki67, anticorps NIFK
Sujet
Antigen Ki-67 is a nuclear protein expressed as two isoforms with molecular weights of 395 and 345 kD. Both isoforms contain one forkhead-associated domain and 16 concatenated "Ki-67 repeats," each containing the epitope recognized by the mAb Ki-67. The antigen Ki-67 interacts with Hklp2, hNIFK, and chromobox protein homolog 1, 3, and 5. Ki-67 is required for cell proliferation and its expression is restricted to the phases G1, S, G2, and M of the cell cycle. This characteristic makes Ki-67 an excellent marker for proliferating cells and is commonly used as one of the prognostic factors in cancer studies. Ki-67 has also been used to study myocyte proliferation after myocardial infarction as well as lymphocyte proliferation during infection, and has been used in neurons of patients with different neuropathologies.